How to Accelerate Nanobody Discovery with High-Throughput Flow Cytometry

Join this webinar to learn more about the new generation of therapeutic antibodies and find out how solutions from Sartorius can be used to accelerate their identification

27 May 2019

Charlie Carter

Life Sciences Editor

While antibodies are set to be increasingly important as therapeutic options for cancer and other diseases, the discovery of fully functional antibodies that lack light chains in Camelidae (camels and llamas) has opened the door to an exciting new generation of therapeutic antibodies known as nanobodies.

Unlike conventional antibodies, the heavy-chain antibodies of Camelidae contain a single variable domain (VHH) and two constant domains (CH2 and CH3) only. Using these functional antibodies as a base, nanobodies – small, single-domain antibody fragments that retain full antigen-binding capabilities and the properties of heavy-chain antibodies – have been created.

In this expert webinar, Pieter Kennis, Associate Scientist for the high-throughput profiling unit at Ablynx, discusses these proteins. Through multiplexing of primary screening assays and semi-automated dose response binding data analysis, we explore antibody binding using the Intellicyt^® iQue Screener to accelerate lead identification.

Watch this expert webinar to learn about:

Efficient labeling of cells using MultiCyt encoder dye
Multiplexing of cell lines encoded with MultiCyt dyes to screen for compound binding (through examples from nanobody discovery campaigns)
Semi-automated data analysis with ForeCyt software to determine EC50 values from dose-response binding

The live webinar will take place on Tuesday, June 11, 2019, at: